InvestorsHub Logo
Followers 4
Posts 1195
Boards Moderated 0
Alias Born 10/03/2015

Re: None

Tuesday, 08/16/2016 9:44:35 AM

Tuesday, August 16, 2016 9:44:35 AM

Post# of 977
Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced it has raised $86 million in Series A venture financing.

The Series A financing was co-led by RiverVest Venture Partners (including 3×5 RiverVest Fund), Novo Ventures, Roche Venture Fund and S.R. One, Limited (the corporate venture capital arm of GlaxoSmithKline).